Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer
Cancers · 11.06.2026 · 18 (12) · 1901
DOI: 10.3390/cancers18121901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 11.06.2026. Verfasst von Makenna A Smack und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marther fund, Mark Mobius fund.
Abstract (Originalsprache)
Background
Gemcitabine, cisplatin and durvalumab or pembrolizumab are standard first-line treatments for advanced or metastatic biliary tract cancer (BTC). Older patients with BTC may be frail or have contraindications to cisplatin. At our institution, oxaliplatin has been used as an alternative to cisplatin.
Methods
In this evaluation, we report the safety and efficacy of gemcitabine with oxaliplatin and durvalumab as a first-line treatment of BTC. The primary objective was overall survival (OS). Secondary objectives included time to progression (TTP), disease control rate (DCR), and the incidence of treatment-related toxicities.
Results
Twenty-nine patients were included. The majority were Caucasian (97%) and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 (97%). Median age was 72 years old. Sixty-six percent had intrahepatic cholangiocarcinoma. Baseline renal insufficiency and/or hearing impairment were the most common reasons for cisplatin contraindication. Median follow-up was 20.6 months. Treatment cycles were every 28 days with durvalumab (1500 mg) given on day 1 and gemcitabine (range 600 mg/m2–1000 mg/m2) plus oxaliplatin (median dose 70 mg/m2) given on days 1 and 15. Median OS was 15.7 months (95% CI: 6.9-NA), median TTP was 6.7 months (95% CI 3.88-NA), and DCR was 76%. Median time on treatment was 3.15 months. Twelve patients (41%) required a dose adjustment, with myelosuppression as the most common toxicity.
Conclusions
Oxaliplatin, in combination with durvalumab and gemcitabine, is a suitable platinum substitute for advanced BTC patients when cisplatin is contraindicated. Our analysis showed similar efficacy and no new safety concerns. Given the small sample size, our analysis is hypothesis-generating and calls for a larger prospective analysis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Makenna A Smack, Jane E Rogers, Ahmed O Kaseb
Förderung
- Marther fund
- Mark Mobius fund
Zitieren
APA
Smack, M. A., Rogers, J. E., Xiao, L., Lee, S. S., Pant, S., Kaseb, A. O., Smaglo, B. G., Higbie, V., Hu, Z. I., An, A., & Javle, M. (2026). Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer. Cancers, 18(12), 1901. https://doi.org/10.3390/cancers18121901
Vancouver
Smack MA, Rogers JE, Xiao L, Lee SS, Pant S, Kaseb AO, et al. Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer. Cancers. 2026;18(12):1901. doi:10.3390/cancers18121901
BibTeX
@article{Smack2026,
author = {Smack, Makenna A and Rogers, Jane E and Xiao, Lianchun and Lee, Sunyoung S and Pant, Shubham and Kaseb, Ahmed O and Smaglo, Brandon G and Higbie, Victoria and Hu, Zishou Ian and An, Amy and Javle, Milind},
title = {Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {12},
pages = {1901},
doi = {10.3390/cancers18121901}
}
EUVIMED